StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) stock

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%

Tarsus Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Tarsus Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $87.68M, up 48.6% year over year. For fiscal 2025 it was $64.32M, up 20.5% from the year before. The highest annual figure on record is $64.32M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$64.32M+20.5%
FY2024Dec 31, 2024$53.39M+6.1%
FY2023Dec 31, 2023$50.31M+18.0%
FY2022Dec 31, 2022$42.62M+2.2%
FY2021Dec 31, 2021$41.71M+121.6%
FY2020Dec 31, 2020$18.83M+495.4%
FY2019Dec 31, 2019$3.16M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$31.01M+98.9%
Q1 FY2026Mar 31, 2026$22.35M+55.1%
Q4 FY2025Dec 31, 2025$18.04M+6.9%
Q3 FY2025Sep 30, 2025$16.28M+34.3%
Q2 FY2025Jun 30, 2025$15.59M+26.6%
Q1 FY2025Mar 31, 2025$14.41M+19.4%
Q4 FY2024Dec 31, 2024$16.87M+26.8%
Q3 FY2024Sep 30, 2024$12.13M+0.2%
Q2 FY2024Jun 30, 2024$12.32M-1.8%
Q1 FY2024Mar 31, 2024$12.07M-2.3%
Q4 FY2023Dec 31, 2023$13.31M+32.7%
Q3 FY2023Sep 30, 2023$12.11M+10.9%
Q2 FY2023Jun 30, 2023$12.55M+30.6%
Q1 FY2023Mar 31, 2023$12.36M+2.3%
Q4 FY2022Dec 31, 2022$10.03M+24.8%
Q3 FY2022Sep 30, 2022$10.91M+6.9%
Q2 FY2022Jun 30, 2022$9.60M+33.3%
Q1 FY2022Mar 31, 2022$12.08M-25.7%
Q4 FY2021Dec 31, 2021$8.04M+5.9%
Q3 FY2021Sep 30, 2021$10.21M+27.8%
Q2 FY2021Jun 30, 2021$7.20M+314.7%
Q1 FY2021Mar 31, 2021$16.26M+975.5%
Q4 FY2020Dec 31, 2020$7.59M+988.5%
Q3 FY2020Sep 30, 2020$7.99M+1902.8%
Q2 FY2020Jun 30, 2020$1.74M–
Q1 FY2020Mar 31, 2020$1.51M–
Q4 FY2019Dec 31, 2019$697.00K–
Q3 FY2019Sep 30, 2019$399.00K–

More Tarsus Pharmaceuticals figures

See a number that looks wrong?